Sometimes, breaking through scientific barriers requires inventing something new. With over 600 novel instruments under their belt, that’s just what our SPaRCS team has done. Hear two scientists on the team, Andrew Radosevich and David A. Chang-Yen, share how SPaRCS is developing technologies that enable life-changing therapies. This is how we’re building the lab of the future: https://bit.ly/4cyMNaz [Video description: AbbVie scientists Andrew Radosevich and David Chang-Yen share an overview of the SPaRCS team. On-screen text reads, “People. Passion. Possibilities.”]
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Locations
Employees at AbbVie
Updates
-
In June, we partnered with the International Agency for the Prevention of Blindness (IAPB) to lead a session on diabetic eye conditions at 2030 IN SIGHT LIVE in Mexico City. The session brought together global experts for a critical conversation on the importance of a multisectoral approach to improve care for people living with diabetic retinopathy and diabetic macular edema. Explore our research areas and efforts in #EyeCare: https://bit.ly/4fcBI0L #2030InSight
-
-
Today, we announced that Roopal Thakkar has been appointed Chief Scientific Officer for AbbVie. Roopal will lead our R&D organization of more than 14,000 team members as we discover and develop future breakthrough medicines for patients. Read more about the news: https://bit.ly/3XWFh4D
-
-
#ParkinsonsDisease (PD) doesn’t sleep. But by studying the data on its impact on sleep, we can better support patients and help them be more aware of their symptoms. Explore the results from a recent patient survey developed by PD Avengers: https://bit.ly/3xOkrKh [Video description: On-screen text outlines the five most common symptoms PD patients report experiencing during sleep, including frequent awakenings; insomnia; bradykinesia; rigidity; and nocturia. On-screen text, “We are proud to sponsor the PD Avengers SLEEP survey.”]
-
Reminder: Applications for the Golden Ticket competition from University Lab Partners, supported by Allergan Aesthetics, close on July 8. Aesthetic #startups are invited to apply – see more details below. ⬇
Advancing the frontier of medical aesthetics depends on investing in the bright minds of tomorrow. That’s why we’re proud to support the 2nd annual Golden Ticket competition with University Lab Partners. Open to aesthetic startup leaders, we invite you to take advantage of this opportunity to win a lab bench for one year with state-of-the-art scientific facilities and equipment, proper environmental health and safety disposal measures, access to UCI core facilities, and complimentary memberships to prominent life science trade associations. Applications are open until July 8, apply today! https://lnkd.in/gt5gM8gN
-
-
In partnership with the PD Avengers, we sponsored a SLEEP survey to better understand the 24-hour nature of #ParkinsonsDisease (PD) and its impact on patients and their care partners. Learn more about the survey results here: https://bit.ly/3XQfTxM [Video description: On-screen text reads, “96% of Parkinson’s disease (PD) patients or their care partners reported that the disease affects their sleep quality, with an average of 2.75 sleep disruptions per night. We are proud to sponsor the PD Avengers SLEEP survey.”]
-
Meet Anthony Omlor, an associate manager of operations on our AbbVie Endocrinology Inc. (AEI) team. He discusses being a leader and how AEI has an impact on patients’ lives. Explore our #careers: https://bit.ly/4cmZWmU [Video description: Anthony Omlor, associate manager, operations, explains his career at AbbVie and the role of AEI while leaving his house; arriving to the office; arriving to his desk; engaging with co-workers; and waving goodbye.]
-
As Rob Michael steps in as our new Chief Executive Officer, Richard A. Gonzalez, executive chairman, reflects on his time as CEO. Read 3 reasons why he believes our best days are ahead: https://bit.ly/4bqfrt4
-
-
#Migraine affects more than 1 billion people worldwide, and we are committed to understanding the complexities behind this debilitating disease. This week, we’re showcasing our research and innovation in neuroscience at the European Academy of Neurology Congress. Learn about our focus on preserving personhood for patients: https://bit.ly/3W5bGog #EAN2024 [Video description: Laurent Delahaye, Ph.D., Global Medical Director, Migraine, AbbVie, says, “Migraine affects all aspects of patients’ lives and we understand the importance of early diagnosis and personalized treatment options to decrease burden and bring patients back to function daily. Every day we are driven by these challenges to support patients and innovate for bringing new solutions to HCPs.”]
-
As another impactful Week of Possibilities comes to an end, follow a #DayInTheLife with Kailee, one of our summer #interns, as she volunteers at one of the hundreds of volunteer projects coordinated by the AbbVie Foundation around the world. Bernie's Book Bank #AbbVieGivesBack [Video description: A summer intern’s POV while volunteering, including footage of: walking into a building, book displays, signing in at check-in table, receiving instructions, sorting books with colleagues, posing with AbbVie Gives Back and “Thank You” signage.]
Affiliated pages
Similar pages
Browse jobs
Stock
ABBV
NYSE
20 minutes delay
$170.28
0.37 (0.218%)
- Open
- 170.63
- Low
- 169.9
- High
- 171.625
Data from Refinitiv
See more info on